Date: {{$ActivityAssignDate}}

Dear Dr. {{ $doctorName }},

Subject : A Survey-Based Comparative Analysis of Beta Blockers in Coronary Artery Disease (COMPCAD Survey)

CAD accounted for 16.2% of all-cause deaths and 7.19% of disability-adjusted life years (DALY) worldwide in 2019.CAD includes acute conditions like unstable angina (UA), acute myocardial infarction (AMI), and sudden cardiac death (SCD), as well as chronic conditions like stable angina and ischemic cardiomyopathy. Treatment has evolved from nitrates in 1880 to modern therapies including β-blockers, coronary artery bypass graft surgery, calcium channel blockers, percutaneous coronary intervention, aspirin, antiplatelet agents, and statins. These advancements have significantly reduced cardiovascular mortality and morbidity.

Beta blockers are first-line therapy for chronic stable angina and recommended for patients with recent myocardial infarction or left ventricular ejection fraction (LVEF) ≤50%. They are not recommended for long-term use in patients without these conditions. Beta blockers vary in selectivity for β1- vs. β2- and α-adrenoceptors, partial agonist activity, vasodilatory properties, and lipophilicity. Cardioselectivity (β1-adrenoceptor selectivity) reduces adverse effects like cold extremities, erectile dysfunction, and exacerbation of asthma or COPD. Beta blockers are recommended for antihypertensive treatment and can be combined with other agents for effective blood pressure control.

We, at Sun Pharma, always strive to be abreast about the current clinical practices, and perceptions about existing treatment options. The aim of this survey is to identify the most effective beta blockers for various coronary artery disease (CAD) conditions, enabling personalized treatment plans, optimizing resource allocation, enhancing patient quality of life by minimizing side effects and maximizing therapeutic benefits, and addressing current uncertainties in beta blocker use to promote more evidence-based and effective treatments. Therefore, the choice of the appropriate β-blocker for each patient will result in the best possible results with fewer side effects. Your responses will be used at an aggregate level.